Brief: Revive Therapeutics inititates Phase 2 study of revenue-004 (bucillamine) in cystinuria
07/02/2017 12:00
Feb 7 (Reuters) - Revive Therapeutics Ltd RVV.V
* Revive Therapeutics announces initiation of a Phase 2
study of revenue-004 (bucillamine) in cystinuria
Source text for Eikon: ID:nCCN85Llhl
Further company coverage: RVV.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure